Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Clinical progress to drive R&D expense on specialty portfolio
Sun Pharma (SUNP) delivered better-than-expected operating performance in 1QFY24. The steady traction in specialty sales, higher US generics sales and controlled opex led to 12% beat on EBITDA. The R&D expense is likely to pick-up over the coming quarter due to progress in major clinical programs.
* We raise our earnings estimates by 3.4%/5.0% for FY24/FY25 to factor in: a) better off-take in the US generics, and b) improved profitability. We value SUNP at 26x 12M forward earnings to arrive at our TP of INR1,310.
* We remain positive on SUNP backed by its: a) robust innovative products franchise targeted for global markets and b) superior execution in branded generics markets. Reiterate BUY.
Better product mix drives margin YoY/QoQ
* SUNP’s 1QFY24 sales rose 11% YoY to INR118b (in line).
* The US sales grew 12% YoY to USD471m (33% of sales). DF sales rose 5% YoY to INR35.6b (30% of sales). EM sales increased 6.5% YoY to USD261m (18% of sales). ROW sales grew 2.7% YoY to USD195m (14% of sales). Global specialty sales jumped 21.5% YoY to USD232m during the quarter.
* GM expanded 380bp YoY to 76.6%, due to better product mix.
* R&D cost was at INR6.8b, forming 5.8% as a % of sales.
* EBITDA margin expanded 230bp YoY to 26.9% (our estimate: 23.8%), fueled by better GM and lower other expenses (down 80bp YoY as a % of sales). However, some of this benefit was offset by higher staff cost (up 90bp YoY as a % of sales). R&D cost was up 140bp YoY as a % of sales.
* EBITDA rose 21% YoY to INR31.7b (our est.: INR28.4b) in 1QFY24.
* There was an exceptional item related to: a) impairment charge (INR1.5b), b) forex loss of INR1.2b and c) impact of planned relocation of Alchemee operation (INR507m) during the quarter.
* Adjusting for this, PAT was up 19% YoY to INR22.8b (our est: INR22b) due to higher tax rate of 16.7% (vs. 8.8% in 1QFY23).
Highlights from the management commentary
* Guidance maintained for R&D expense (as a % of sales) at 7-8% for FY24.
* SUNP has taken steps to accelerate phase III trials for Ilumya in terms of enrolments of patients.
* The seasonality related to levulan affected specialty sales adversely to some extent for the quarter.
* SUNP did not witness any adverse impact of Humira biosimilar on Ilumya.
* SUNP would be starting phase II trials for GL0034 shortly.
To Read Complete Report & Disclaimer Click Here
For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
Above views are of the author and not of the website kindly read disclaimer
